Answers are grounded in this paper and cite their sources.
Background: G protein-coupled receptors (GPCRs) can recognize endogenous small-molecule metabolites and are important regulators of cardiovascular diseases associated with metabolic disorders; however, their comprehensive classification and translational value remain to be clarified. Methods: This narrative review synthesizes recent research findings on endogenous metabolite-activated GPCRs, summarizes ligand-receptor pairings for the various GPCR classes, analyzes downstream signaling pathways and the regulatory mechanisms underlying cardiovascular pathology, and evaluates the evidence supporting these receptors as potential drug targets. Only studies addressing endogenous metabolite-GPCR interactions were included; exogenous drugs and synthetic ligands were excluded unless used as pharmacological tools. Results: Metabolites such as short-chain fatty acids, ceramides, bile acids, and succinate interact with their respective GPCRs and are involved in cardiovascular pathophysiology, including blood pressure regulation, atherosclerosis, myocardial injury, and aortic dissection. Some of these metabolites can serve as diagnostic biomarkers, and intervention strategies targeting this axis hold therapeutic potential. Through structured appraisal of evidence strength, druggability, and tissue-specific expression, we identify SUCNR1 (GPR91), GPBAR1 (TGR5), and the ceramide receptor complex CYSLTR2/P2RY6 as high-priority candidates for drug development, with GPR35, LPAR subtypes, and hydroxycarboxylic acid receptor 2 (HCAR2, also known as HCA2/GPR109A) considered moderate-priority candidates. Conclusions: The metabolite-GPCR axis links metabolism and cardiovascular disease, providing new targets and approaches for its diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: